No Detail Found!

Short-term efficacy of intravitreal bevacizumab in treatment naive patients- real world evidence in pakistan

Author(s)
Hajra Arshad Malik Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan
Rayyan Sabih Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan
Maham Khalid Medical Retina Clinic, Amanat Eye Hospital,Rawalpindi, Pakistan
Hina Khan Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan
Maha Asrar Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan
Aamir Asrar Medical Retina Clinic, Amanat Eye Hospital,Rawalpindi, Pakistan
Muhammad Asif Medical Retina Clinic Medical Retina Clinic, Amanat Eye Hospital, Rawalpindi, Pakistan
Abstract
Background: Anti-VEGF agents have been proven to be effective in treating macular oedema secondary to a multitude of pathological conditions. However, in large clinical trial settings, the results may be overstated. This study aimed to evaluate the short-term efficacy of intraocular Bevacizumab in consecutive patients with macular oedema being treated in a 'real-world' setting in Pakistan. Methods: A prospective study was conducted at Amanat Eye Hospital, Rawalpindi from August 2018 to November 2019. Thirty-five eyes of 29 patients with macular oedema were treated with monthly intravitreal Bevacizumab injections for three consecutive months. Bestcorrected visual acuity (BCVA), and OCT parameters including central retinal thickness (CRT) and macular volume were assessed prior to the injections and then 4 weeks post the final injection and compared. Results: BCVA improved from 1.00±0.44 at baseline to 0.83±0.48 four weeks after the third intravitreal injection. CRT decreased significantly from 492.77±192.31 at baseline to 362.91±126.11 (p<0.05), and macular volume decreased significantly from 11.61±2.39 at baseline to 9.87±1.68 (p<0.05) four weeks after the third intravitreal injection. No systemic or ocular complications were observed during the course of the study. Conclusion: Treatment with intravitreal Bevacizumab injections was found safe and resulted in clinically and statistically significant improvement in SD-OCT parameters and visual acuity in patients with macular oedema secondary to various retinal pathologies. However, the improvement in a real-world setting was sub-optimal in comparison to larger clinical trials for specific diseases in the developed world.
Publication Details
Page(s) 183-187
DOI DOI not available
Published Journal: Journal of Ayub Medical College, Volume: 33, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Diabetic Retinopathy, Bevacizumab, Macular Oedema, Retinal Vein Occlusion, Macular Degeneration
0

Citations

0

Downloads

35

Views